October 31, 2017

UMMS develops rabies vaccine with Indian manufacturer

File photo
A new rabies vaccine developed by UMass Medical School should reduce prevention gaps in India.

An Indian vaccine manufacturer and UMass Medical School announced Tuesday the global launch of a rabies antibody.

The disease kills an estimated 20,000 people every year -- two an hour -- in India, according to a press release.

The U.S.-patented product, Rabishield, is expected to significantly reduce the mortality rate and close rabies prevention gaps. It was developed by scientists at MassBiologics of UMass Medical School and manufactured by the Serum Institute of India.

According to UMass Medical School Chancellor Michael Collins, rabies is rare in the U.S., but kills more than 50,000 people a year worldwide.

The monoclonal antibody is more potent and is easier to manufacture the existing globulin treatment, which is effective, but are in short supply. The new antibody offers a passive immunization against all rabies serotypes found in India. It is manufactured by recombinant DNA technology and requires a lower dose than globulins.


Type your comment here:

Today's Poll What does your company do to protect its data?<>
Most Popular on Facebook
Copyright 2017 New England Business Media